NCT07476326 2026-03-17Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With MelanomaBiocon LimitedPhase 1 Not yet recruiting120 enrolled